HR Execs on the Move

Chemica Technologies Inc

www.chemica.com

 
Chemica Technologies Inc is a Beaverton, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

GEORGE FISCHER SIGNET INC

GEORGE FISCHER SIGNET INC is a El Monte, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical

Ipsen

Ipsen S.A. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Cascade Healthcare Solutions

After beginning as a successful online company in 2009, Cascade Healthcare Solutions recently decided to open a physical store in Renton, Washington. Now we are able to meet the needs of our Local Customers, while maintaining a national online presence...

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.